Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the anti-emetic effect of oral ondansetron. For this evaluation, the investigators will perform a multi-center, double-blind, placebo-controled, randomized study. The investigators assumption is that oral ondansetron prior to intramuscular ketamine will reduce the occurrence of ketamine-induced vomiting.


Clinical Trial Description

Methods

- a multi-center, double-blind, placebo-controled, randomized study ( 4 tertiary hospital ED)

- survey for the occurrence of vomiting at ED and after discharge

Primary outcome

- the number of vomiting at ED and at home

Secondary outcome

- parent's satisfaction and ED length of stay ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01477242
Study type Interventional
Source Seoul National University Hospital
Contact Do Kyun Kim, M.D.
Phone 82-2-2072-0238
Email birdbeak@naver.com
Status Recruiting
Phase N/A
Start date November 2011
Completion date May 2012

See also
  Status Clinical Trial Phase
Completed NCT04696445 - Pharmacokinetics of Morphine and Oxycodone in Frail Elderly Undergoing Cardiac Surgery
Recruiting NCT05775419 - Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC N/A
Completed NCT06035900 - Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate Phase 1
Completed NCT04475029 - Methadone in Cystectomy Patients N/A
Recruiting NCT03996941 - Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)
Recruiting NCT04701151 - NORTH-REG Dwell-Time Study Phase 4
Not yet recruiting NCT04644354 - The Efficacy of Nifedipine in the Management of Preterm Labor
Completed NCT03183908 - FLUAD® vs. Fluzone® High-Dose Study Phase 4
Not yet recruiting NCT06322238 - Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice: Phase 2